Online inquiry

IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3390MR)

This product GTTS-WQ3390MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets Canlupfam CD52 gene. The antibody can be applied in Canine T-cell lymphoma research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Caninized
RefSeq NM_001003240.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 403918
UniProt ID Q28896
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ3390MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11524MR IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MFGR1877S
GTTS-WQ14519MR IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SA-237
GTTS-WQ15453MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA U3-1287
GTTS-WQ1027MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-399
GTTS-WQ10452MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY2541546
GTTS-WQ12079MR IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MOR-00208
GTTS-WQ5497MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDP 6038
GTTS-WQ6424MR IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CT-P22
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW